AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
← catalyst calendarNCT07094113 · readout in 608 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
434estimated
Sites
39
Countries
Australia, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-31 | actual | When the study began enrolling |
| Primary completion | 2028-04-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- KRAS Altered Advanced or Metastatic Solid Tumors
Interventions
- Drug: AMG 410
- Drug: Pembrolizumab
- Drug: Panitumumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose Limiting Toxicities (DLTs)
measured Up to 28 days
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
measured Up to approximately 3 years
Number of Participants with Serious Adverse Events (SAEs)
measured Up to approximately 3 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed